- Home
- ARHS vs IMNM Comparison
ARHS vs IMNM Comparison
Compare ARHS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | IMNM |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARHS | IMNM |
|---|---|---|
| Price | $11.73 | $22.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $11.81 | ★ $31.44 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,361,388,000.00 | $9,679,000.00 |
| Revenue This Year | $9.59 | N/A |
| Revenue Next Year | $6.46 | $11.53 |
| P/E Ratio | $22.56 | ★ N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $6.61 | $5.15 |
| 52 Week High | $13.02 | $25.30 |
Technical Indicators
Market Signals| Indicator | ARHS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 67.31 | 61.19 |
| Support Level | $11.30 | $19.37 |
| Resistance Level | $11.89 | $25.30 |
| Average True Range (ATR) | 0.48 | 1.48 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 72.35 | 54.24 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.